



Solos Endoscopy, Inc.
www.solosendoscopy.com
(OTCPK: SNDY)

January 10, 2014

Dear Solos Endoscopy, Inc. Shareholders,

I am very pleased to be able to communicate with our loyal shareholders directly and to give you an update on our progress this year.

Solos Endoscopy, Inc. has been at the forefront of breakthrough medical devices and technologies for the treatment and management of diseases for over 25 years. The Company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.

Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD as well as Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.

Looking forward in 2014, Solos Endoscopy's ISO 13485:2003 certification will allow the company to sell the MammoView® product line in Europe and Canada. As part of the process to obtain the CE Mark, Solos Endoscopy retained Emergo Group to act as the Company's authorized representative in Europe. Emergo Group will provide Solos assistance related to communications with authorities and importation of Solos instruments into Europe.

Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease. These products will allow the physician to examine organs and tissues within the body without the need for intrusive surgery. The Company is currently marketing its next generation breast endoscopy system, the MammoView® system, for early breast cancer detection.

Solos Endoscopy, as a public Company, continues to update its shareholders through regular postings on www.otcmarkets.com and through Company press releases. Solos Endoscopy posted a disclosure regarding a notice it received from the Depository Trust Company (DTC) on November 25, 2013. Since that time, Solos Endoscopy's legal counsel provided DTC a legal opinion, on December 19, 2013, to confirm that each of the Subject Securities, including the Notice Securities, were, at the date of deposit at DTC, eligible under the Rules and Procedures of DTC to be deposited for the Services.

To learn more information about the Company and its products visit www.solosendoscopy.com. I want to thank all our loyal shareholders and I look forward to a successful 2014.

Regards,



Robert Segersten
President and CEO
Solos Endoscopy, Inc.

Certain statements in this document may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this document, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.